**1. Introduction**

Sarcomas are malignant uncommon heterogeneous tumors [1] derived from mesenchymal tissues [2, 3]. There are mainly bone and soft tissue sarcomas (4:1), accounting for 1% of all cancers [2]. They are responsible for 19%−21% of cancer deaths [2]. Low frequency, high diversity, and limited knowledge about the underlying biological mechanisms make it difficult to treat sarcomas [1, 2]. Chemoresistance, local recurrences (10–20%) [4], and metastatic disease (33%) are still unresolved clinical problems with no new critical improvement in sarcomas treatment [2]. In these tumors about onethird of sarcoma patients die, so it is imperative to find new therapeutic strategies for sarcomas. Since lipids, especially those derived from the cholesterol pathway, play an

important role in tumorigenesis, the purpose of this review is to update the function played by cholesterol in the treatment of sarcomas and to assess whether statins can have a place in the therapeutic treatment of sarcomas.
